SCHEMBL588658

SCHEMBL588658

COC(Cc1ccccc1N)OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
TDP1 Q9NUW8 2/20 0.40
ADRA2B P18089 1/20 0.40
PTGS1 P23219 1/20 0.40
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CFTR P13569 1/20 0.34
HSD17B10 Q99714 1/20 0.34
IDO1 P14902 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
FDPS P14324 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
RCE1 Q9Y256 1/20 0.34
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3854634 0.84 CD44 (0.39) ALDH1A1TDP1ADRA2BPTGS1CYP3A4
SCHEMBL18658983 0.77 TAAR1 (0.43) PTGS1CYP3A4TAAR1KDM4EKMT2A
SCHEMBL270111 0.76 GABRA1 (0.52) TDP1CYP3A4ALOX15CASP1CASP7
SCHEMBL2478903 0.75 IDO1 (0.45) ALDH1A1SMN1; SMN2HSD17B10IDO1TAAR1
SCHEMBL31230581 0.75 HSPA5 (0.48) CYP3A4IDO1TAAR1
SCHEMBL3211513 0.75 IDO1 (0.45) ALDH1A1TDP1IDO1TAAR1
SCHEMBL4715427 0.75 CYP3A4 (0.44) ALDH1A1TDP1CYP3A4ALOX15SMN1; SMN2
SCHEMBL4990649 0.75 CD44 (0.42) CYP3A4TAAR1
SCHEMBL12367380 0.75 CYP3A4 (0.43) ALDH1A1TDP1CYP3A4ALOX15SMN1; SMN2
SCHEMBL1724429 0.74 SLC6A2 (0.52) TAAR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552815-B2 Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof QPEX BIOPHARMA, INC. (US) 2026-02-17 US disclosed
CN-111212843-B Boric acid derivatives and synthesis thereof QPEX生物制药有限公司 2025-05-16 CN disclosed
WO-2025050647-A1 IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 晟迪生物医药(苏州)有限公司 2025-03-13 WO disclosed
EP-3694864-B1 BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF QPEX BIOPHARMA INC (US) 2025-03-05 EP disclosed
US-20250002508-A1 BORONIC ACID DERIVATIVES AND SYNTHESIS, POLYMORPHIC FORMS, AND THERAPEUTIC USES THEREOF QPEX BIOPHARMA, INC. 2025-01-02 US disclosed
US-20240279248-A1 SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF MELINTA SUBSIDIARY CORP. 2024-08-22 US disclosed
CN-118388347-A Compound, borate derivative formed from compound and preparation method of borate derivative 梅琳塔治疗公司 2024-07-26 CN disclosed
US-11999757-B2 Synthesis of boronate ester derivatives and uses thereof MELINTA SUBSIDIARY CORP. (US) 2024-06-04 US disclosed
CN-111556872-B Synthesis of borate derivatives and uses thereof 梅琳塔治疗公司 2024-05-10 CN disclosed
CN-117986153-A Ionizable cationic lipid compound, and preparation method and application thereof 晟迪生物医药(苏州)有限公司 2024-05-07 CN disclosed
US-20070270465-A1 CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4-[1-(PYRIDIN-2-YLMETHYL) PIPERIDIN-4-YL]-1H-INDOL-3-YL]-1H-PYRROLE MONO-HYDROCHLORIDE BUSH JULIE K 2007-11-22 US disclosed
EP-1523313-B1 CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4- 1-(PYRIDIN-2-YLMETHYL)PIPERIDIN-4-YL -1H-INDOL-3-YL -1H-PYRROLE MONO-HYDROCHLORIDE LILLY CO ELI (US) 2007-11-21 EP disclosed
EP-1487822-B1 PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS LILLY CO ELI (US) 2007-08-01 EP disclosed
US-20070004764-A1 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-01-04 US disclosed
US-20050288332-A1 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2ylmethyl)piperidin-4-yl]-1h- pyrrole mono-hydrochloride DENOVO BIOPHARMA LLC 2005-12-29 US disclosed
US-20050288321-A1 Kinase inhibitors ELI LILLY AND COMPANY 2005-12-29 US disclosed
EP-1523313-A1 CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4- 1-(PYRIDIN-2-YLMETHYL)PIPERIDIN-4-YL]-1H-INDOL-3-YL]-1H-PYRROLE MONO-HYDROCHLORIDE ELI LILLY AND COMPANY (US) 2005-04-20 EP disclosed
EP-1487822-A2 PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS ELI LILLY AND COMPANY (US) 2004-12-22 EP disclosed
WO-2004006928-A1 CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4-[1-(PYRIDIN-2-YLMETHYL)PIPERIDIN-4-YL]-1H-INDOL-3-YL]-1H-PYRROLE MONO-HYDROCHLORIDE ELI LILLY AND COMPANY (US) 2004-01-22 WO disclosed
WO-2003076398-A2 PYRROLE-2, 5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS ELI LILLY AND COMPANY (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288332-A1 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2ylmethyl)piperidin-4-yl]-1h- pyrrole mono-hydrochloride IDO1, PYCR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ALDH1A1 1567/4885TDP1 1869/4885ADRA2B 2844/4885
US-20250002508-A1 BORONIC ACID DERIVATIVES AND SYNTHESIS, POLYMORPHIC FORMS, AND THERAPEUTIC USES THEREOF BLVRB, BBC3, BPGM ALDH1A1 1049/4885TDP1 688/4885ADRA2B 1393/4885
US-20070270465-A1 CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4-[1-(PYRIDIN-2-YLMETHYL) PIPERIDIN-4-YL]-1H-INDOL-3-YL]-1H-PYRROLE MONO-HYDROCHLORIDE IDO1, MKI67, PYCR1 ALDH1A1 1248/4885TDP1 2162/4885ADRA2B 3074/4885
US-11999757-B2 Synthesis of boronate ester derivatives and uses thereof ADH5, ADH1A, ADH7 ALDH1A1 69/4885TDP1 1727/4885ADRA2B 999/4885
US-20070004764-A1 Nitrogen-containing aromatic derivatives NR0B2, NR0B1, NR4A1 ALDH1A1 1501/4885TDP1 4358/4885ADRA2B 162/4885
US-20240279248-A1 SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF ADH5, ADH1A, ADH7 ALDH1A1 69/4885TDP1 1727/4885ADRA2B 999/4885
US-12552815-B2 Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof BBC3, BLK, BRCA1 ALDH1A1 1964/4885TDP1 228/4885ADRA2B 1586/4885
US-20050288321-A1 Kinase inhibitors ABL1, MAP3K20, MAP3K19 ALDH1A1 3292/4885TDP1 1549/4885ADRA2B 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.